Details of Disease

General Information of Disease (ID: DISAE66J)

Disease Name	Lewy body dementia
Synonyms	dementia, Lewy body; diffuse Lewy body disease; diffuse Lewy body disease with gaze palsy; Lewy body variant of Alzheimer disease; cortical Lewy body disease; Lewy body disease; DLB; Lewy body dementia; Senile dementia of the Lewy body type; lewy body dementia, susceptibility to; dementia with Lewy bodies
Disease Class	6D80-6D8Z: Dementia
Definition	A progressive form of dementia characterized by the presence of protein deposits called Lewy bodies in the midbrain and cerebral cortex, and loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer and Parkinson disease.
Disease Hierarchy	DISFWL8F: Hereditary dementia DISFEF6X: Synucleinopathy DISAE66J: Lewy body dementia
ICD Code	ICD-11 ICD-11: 6D82 Expand ICD-11 '6D82
Disease Identifiers	MONDO ID MONDO_0007488 MESH ID D020961 UMLS CUI C0752347 OMIM ID 127750 MedGen ID 199874 Orphanet ID 1648 SNOMED CT ID 312991009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
E2027	DMK8SY6	Phase 2	Small molecular drug	[1]
NELOTANSERIN	DM4LKFO	Phase 2	Small molecular drug	[2]
RVT-104	DM1INL2	Phase 1	NA	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 40 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ANK1	TTKFPMH	Limited	Posttranslational Modification	[3]
APP	TTE4KHA	Limited	Biomarker	[4]
BACE1	TTJUNZF	Limited	Altered Expression	[5]
DLG4	TT9PB26	Limited	Altered Expression	[6]
DYRK1A	TTSBVFO	Limited	Biomarker	[7]
ECE2	TT5U914	Limited	Altered Expression	[8]
F11	TTDM4ZU	Limited	Biomarker	[9]
FABP3	TT3TGLR	Limited	Altered Expression	[10]
FKBP1A	TTMW94E	Limited	Biomarker	[11]
FYN	TT2B9KF	Limited	Biomarker	[11]
KLK6	TTLPF4X	Limited	Biomarker	[12]
PSEN2	TTWN3F4	Limited	Genetic Variation	[13]
PSMB8	TTEAD9J	Limited	Altered Expression	[14]
RPH3A	TT9L4J8	Limited	Biomarker	[15]
SUGT1	TT7Q9WR	Limited	Altered Expression	[16]
UBC	TTBP3XA	Limited	Altered Expression	[17]
UCHL3	TT23UD6	Limited	Altered Expression	[17]
CIT	TT3BKTU	Disputed	Biomarker	[18]
BCHE	TT3MSAO	moderate	Biomarker	[19]
MAPT	TTS87KH	moderate	Genetic Variation	[20]
PSEN1	TTZ3S8C	moderate	Genetic Variation	[13]
TARDBP	TT9RZ03	moderate	Biomarker	[21]
ACHE	TT1RS9F	Strong	Biomarker	[22]
AGER	TTMO9HF	Strong	Biomarker	[23]
AIF1	TT12MEP	Strong	Biomarker	[24]
BECN1	TT5M7LN	Strong	Biomarker	[25]
EDN1	TTJR60Z	Strong	Altered Expression	[26]
GBA	TT1B5PU	Strong	Genetic Variation	[27]
IGF1R	TTQFBMY	Strong	Biomarker	[24]
IGF2	TTE8WGO	Strong	Biomarker	[24]
IGF2R	TTPNE41	Strong	Biomarker	[24]
INS	TTZOPHG	Strong	Biomarker	[24]
INSR	TTCBFJO	Strong	Biomarker	[24]
MAG	TT9XFON	Strong	Biomarker	[24]
NGF	TTDN3LF	Strong	Biomarker	[28]
NTRK1	TTTDVOJ	Strong	Biomarker	[24]
NTRK2	TTKN7QR	Strong	Biomarker	[24]
SNCA	TT08OSU	Strong	Autosomal dominant	[29]
GFAP	TTI6FFX	Definitive	Biomarker	[30]
TPO	TT52XDZ	Definitive	Biomarker	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 40 DTT(s)

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR7A2	DE4G629	moderate	Biomarker	[32]
------------------------------------------------------------------------------------

This Disease Is Related to 73 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ABI3	OTQTDSHP	Limited	Genetic Variation	[33]
AFF1	OTT2C78E	Limited	Biomarker	[34]
AFM	OTPOR8IO	Limited	Biomarker	[35]
ALDH1L1	OT15HOJX	Limited	Biomarker	[30]
BHLHE22	OTZUQY5L	Limited	Biomarker	[36]
BPIFA2	OTLFSDZD	Limited	Biomarker	[31]
CALB1	OTM7IXDG	Limited	Biomarker	[37]
CAMK2A	OTJGX19T	Limited	Altered Expression	[38]
CHMP2B	OTZA7RJB	Limited	Biomarker	[39]
CHORDC1	OT3W6F1U	Limited	Altered Expression	[16]
CYP2D7	OTYJTL3S	Limited	Genetic Variation	[40]
ECD	OT3L3PCU	Limited	Altered Expression	[16]
EEF1A1	OT00THXS	Limited	Biomarker	[6]
EIF4G1	OT2CF1E6	Limited	Genetic Variation	[41]
GPR78	OT8TKE6F	Limited	Altered Expression	[42]
KCNH4	OTHJ8WTU	Limited	Biomarker	[43]
KCNH8	OT3I5FLB	Limited	Biomarker	[43]
LAD1	OT6YGTVX	Limited	Biomarker	[44]
MAP1A	OTHO8K43	Limited	Biomarker	[45]
MASP1	OTWWCNZP	Limited	Biomarker	[45]
MOAP1	OTVF3LUG	Limited	Biomarker	[45]
MYO5C	OTKLOCWZ	Limited	Altered Expression	[46]
NANOS3	OTGX9IQU	Limited	Biomarker	[47]
NBEAL1	OTLJ11N3	Limited	Biomarker	[48]
NEFL	OTQESJV4	Limited	Genetic Variation	[49]
NEUROD6	OTLFL6K8	Limited	Biomarker	[50]
NRGN	OTVGE10W	Limited	Biomarker	[51]
NUB1	OTWA6RTX	Limited	Posttranslational Modification	[52]
PDHA1	OTGEU8IK	Limited	Biomarker	[53]
PHYHD1	OTTKHTAC	Limited	Altered Expression	[46]
PINK1	OT50NR57	Limited	Biomarker	[54]
PLA2G6	OT5FL0WU	Limited	Biomarker	[55]
PLCG2	OTGVC9MY	Limited	Genetic Variation	[33]
PRSS2	OTOMVUWL	Limited	Altered Expression	[56]
PSPH	OTV1PVAX	Limited	Biomarker	[31]
PSPN	OT54LLZJ	Limited	Biomarker	[31]
PTCRA	OTQTO5QZ	Limited	Biomarker	[9]
RAB39B	OTDCLLT0	Limited	Genetic Variation	[57]
REM1	OTUXL0HC	Limited	Biomarker	[58]
RIDA	OTW4098I	Limited	Biomarker	[31]
RPS27A	OTIIGGZ2	Limited	Altered Expression	[17]
SCARB2	OTN929M8	Limited	Altered Expression	[59]
SERPINB6	OT7G55IK	Limited	Biomarker	[60]
SESN3	OTJRY1Y5	Limited	Biomarker	[61]
SGTA	OTKOJ3JB	Limited	Altered Expression	[16]
SMG1	OTTS3SXE	Limited	Altered Expression	[62]
SMUG1	OT2YIOCQ	Limited	Biomarker	[63]
STXBP3	OTTTYMAQ	Limited	Biomarker	[31]
SUCLA2	OTMZD4PW	Limited	Biomarker	[64]
SYNM	OTOI8TRJ	Limited	Biomarker	[11]
SYNPO	OTICDJAB	Limited	Altered Expression	[65]
TIGAR	OTR7NMRJ	Limited	Biomarker	[66]
TMEM230	OTAFALFV	Limited	Biomarker	[67]
TOMM40	OTZDQ29F	Limited	Genetic Variation	[68]
TPPP	OTCFMSUF	Limited	Biomarker	[69]
TPSG1	OTDESHKT	Limited	Biomarker	[70]
TRIM9	OTKYG33W	Limited	Biomarker	[71]
TSHZ1	OTYQ9ECW	Limited	Genetic Variation	[72]
BCL7C	OT8P2IFT	moderate	Genetic Variation	[73]
SNCB	OTELSEK6	Moderate	Unknown	[29]
ASH1L	OTUT5NLJ	Strong	Genetic Variation	[74]
CHCHD2	OTL5PA3Y	Strong	Genetic Variation	[75]
DNAJC13	OTYAVVJ6	Strong	Genetic Variation	[76]
ENO2	OTRODL0T	Strong	Biomarker	[77]
LMTK2	OT93MVIC	Strong	Biomarker	[78]
MAP2	OT6UYT3X	Strong	Biomarker	[79]
PPARGC1A	OTHCDQ22	Strong	Biomarker	[79]
SNCA	OTPWC1MR	Strong	Autosomal dominant	[29]
BRAP	OTB7BAFQ	Definitive	Biomarker	[80]
CHI3L1	OT2Z7VJH	Definitive	Altered Expression	[81]
IMPA1	OTBUVW1Z	Definitive	Biomarker	[80]
LRP10	OT8490HT	Definitive	Genetic Variation	[82]
SNCAIP	OTH8VNOK	Definitive	Biomarker	[83]
------------------------------------------------------------------------------------


⏷ Show the Full List of 73 DOT(s)

References

1	ClinicalTrials.gov (NCT04764669) A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases.Neurobiol Aging. 2019 Feb;74:70-76. doi: 10.1016/j.neurobiolaging.2018.09.024. Epub 2018 Oct 13.
4	Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies.Neurobiol Dis. 2016 Oct;94:55-62. doi: 10.1016/j.nbd.2016.06.004. Epub 2016 Jun 14.
5	BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue.J Alzheimers Dis. 2010;22(4):1111-22. doi: 10.3233/JAD-2010-101254.
6	Early defects in translation elongation factor 1 levels at excitatory synapses in -synucleinopathy.Acta Neuropathol. 2019 Dec;138(6):971-986. doi: 10.1007/s00401-019-02063-3. Epub 2019 Aug 26.
7	A pilot study examining associations between DYRK1A and -synuclein dementias.Neurodegener Dis. 2012;10(1-4):229-31. doi: 10.1159/000334759. Epub 2012 Jan 21.
8	Endothelin-converting enzymes degrade -synuclein and are reduced in dementia with Lewy bodies.J Neurochem. 2017 Apr;141(2):275-286. doi: 10.1111/jnc.13974. Epub 2017 Mar 29.
9	Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation.J Neuroimmunol. 2010 Apr 15;221(1-2):62-7. doi: 10.1016/j.jneuroim.2010.02.004. Epub 2010 Mar 5.
10	Differential role of CSF fatty acid binding protein 3, -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.Alzheimers Res Ther. 2017 Jul 28;9(1):52. doi: 10.1186/s13195-017-0276-4.
11	FKBP12-immunopositive inclusions in patients with -synucleinopathies.Brain Res. 2018 Feb 1;1680:39-45. doi: 10.1016/j.brainres.2017.12.012. Epub 2017 Dec 12.
12	Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of -synuclein in multiple system atrophy.Neuropathol Appl Neurobiol. 2019 Jun;45(4):347-360. doi: 10.1111/nan.12512. Epub 2018 Aug 29.
13	Diffuse Lewy Body Disease and Alzheimer Disease: Neuropathologic Phenotype Associated With the PSEN1 p.A396T Mutation.J Neuropathol Exp Neurol. 2019 Jul 1;78(7):585-594. doi: 10.1093/jnen/nlz039.
14	Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in -Synuclein Aggregation Disorders.EBioMedicine. 2018 May;31:307-319. doi: 10.1016/j.ebiom.2018.05.007.
15	Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease.Neurobiol Dis. 2004 Jun;16(1):92-7. doi: 10.1016/j.nbd.2004.01.001.
16	HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies.J Parkinsons Dis. 2019;9(1):97-107. doi: 10.3233/JPD-181443.
17	Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies.Neurobiol Dis. 2006 May;22(2):265-73. doi: 10.1016/j.nbd.2005.11.005. Epub 2005 Dec 27.
18	Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies.Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1652-1660. doi: 10.1007/s00259-019-04315-6. Epub 2019 Apr 12.
19	Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.Exp Ther Med. 2019 Mar;17(3):1611-1624. doi: 10.3892/etm.2018.7129. Epub 2018 Dec 24.
20	Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant.Acta Neuropathol Commun. 2019 Jan 23;7(1):10. doi: 10.1186/s40478-019-0661-2.
21	Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease.J Alzheimers Dis. 2019;69(4):953-961. doi: 10.3233/JAD-181285.
22	Do Acetylcholinesterase Inhibitors Prevent or Delay Psychotropic Prescribing in People With Dementia? Analyses of the Swedish Dementia Registry.Am J Geriatr Psychiatry. 2020 Jan;28(1):108-117. doi: 10.1016/j.jagp.2019.06.008. Epub 2019 Jun 25.
23	Evidence of oxidative stress in the neocortex in incidental Lewy body disease.J Neuropathol Exp Neurol. 2005 Sep;64(9):816-30. doi: 10.1097/01.jnen.0000179050.54522.5a.
24	Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.J Alzheimers Dis. 2009;16(3):585-99. doi: 10.3233/JAD-2009-0995.
25	Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein.Am J Pathol. 2009 Aug;175(2):736-47. doi: 10.2353/ajpath.2009.080928. Epub 2009 Jul 23.
26	Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies.Brain Pathol. 2014 Jul;24(4):334-43. doi: 10.1111/bpa.12130. Epub 2014 Mar 28.
27	GBA1 mutations: Prospects for exosomal biomarkers in -synuclein pathologies.Mol Genet Metab. 2020 Feb;129(2):35-46. doi: 10.1016/j.ymgme.2019.10.006. Epub 2019 Oct 23.
28	Cerebrospinal fluid from Alzheimer patients affects cell-mediated nerve growth factor production and cell survival in vitro.Exp Cell Res. 2018 Oct 1;371(1):175-184. doi: 10.1016/j.yexcr.2018.08.007. Epub 2018 Aug 6.
29	The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
30	Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies.Front Aging Neurosci. 2018 Apr 26;10:122. doi: 10.3389/fnagi.2018.00122. eCollection 2018.
31	Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates.Can J Psychiatry. 2004 Mar;49(3):164-71. doi: 10.1177/070674370404900303.
32	Genetic variation of Aflatoxin B1 aldehyde reductase genes (AFAR) in human tumour cells.Cancer Lett. 2008 Dec 8;272(1):160-6. doi: 10.1016/j.canlet.2008.07.013. Epub 2008 Aug 26.
33	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans.Mol Neurodegener. 2018 Oct 11;13(1):53. doi: 10.1186/s13024-018-0289-x.
34	Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Acta Neuropathol. 2014;127(6):861-79. doi: 10.1007/s00401-014-1256-4. Epub 2014 Feb 14.
35	ALBA Screening Instrument (ASI): A brief screening tool for Lewy Body Dementia.Arch Gerontol Geriatr. 2017 May-Jun;70:67-75. doi: 10.1016/j.archger.2017.01.001. Epub 2017 Jan 5.
36	Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson's Disease and Dementia with Lewy Bodies.Brain Pathol. 2017 Jan;27(1):3-12. doi: 10.1111/bpa.12344. Epub 2016 Jan 18.
37	Calcipotriol inhibits -synuclein aggregation in SH-SY5Y neuroblastoma cells by a Calbindin-D28k-dependent mechanism.J Neurochem. 2017 Apr;141(2):263-274. doi: 10.1111/jnc.13971.
38	Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein.Exp Neurol. 2015 Feb;264:8-13. doi: 10.1016/j.expneurol.2014.11.003. Epub 2014 Nov 20.
39	Localization of CHMP2B-immunoreactivity in the brainstem of Lewy body disease.Neuropathology. 2013 Jun;33(3):237-45. doi: 10.1111/j.1440-1789.2012.01346.x. Epub 2012 Sep 19.
40	Alternative splicing patterns of CYP2D genes in human brain and neurodegenerative disorders.Neurology. 1999 Oct 22;53(7):1570-2. doi: 10.1212/wnl.53.7.1570.
41	Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia.Acta Neuropathol. 2013 Mar;125(3):425-38. doi: 10.1007/s00401-012-1059-4. Epub 2012 Nov 4.
42	GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson's Disease Patients.Front Neurosci. 2019 Jul 5;13:697. doi: 10.3389/fnins.2019.00697. eCollection 2019.
43	A neurotoxic phosphoform of Elk-1 associates with inclusions from multiple neurodegenerative diseases.PLoS One. 2010 Feb 2;5(2):e9002. doi: 10.1371/journal.pone.0009002.
44	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients.Neurobiol Aging. 2017 Nov;59:1-9. doi: 10.1016/j.neurobiolaging.2017.06.028. Epub 2017 Jul 11.
45	Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies.J Neuropathol Exp Neurol. 2011 Apr;70(4):264-80. doi: 10.1097/NEN.0b013e318211c86a.
46	Genes associated with the progression of neurofibrillary tangles in Alzheimer's disease.Transl Psychiatry. 2014 Jun 10;4(6):e396. doi: 10.1038/tp.2014.35.
47	Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases.J Neurol Sci. 1999 Jan 15;162(2):133-51. doi: 10.1016/s0022-510x(98)00297-4.
48	Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.Parkinsonism Relat Disord. 2019 Jul;64:124-131. doi: 10.1016/j.parkreldis.2019.03.023. Epub 2019 Mar 28.
49	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.Mov Disord. 2019 Jul;34(7):1069-1073. doi: 10.1002/mds.27731. Epub 2019 Jun 12.
50	Differential -synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.Acta Neuropathol. 2018 Jun;135(6):855-875. doi: 10.1007/s00401-018-1829-8. Epub 2018 Mar 3.
51	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders.Curr HIV/AIDS Rep. 2019 Feb;16(1):76-81. doi: 10.1007/s11904-019-00420-1.
52	Phosphorylated NUB1 distinguishes -synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.Brain Pathol. 2019 Nov;29(6):803-812. doi: 10.1111/bpa.12728. Epub 2019 May 17.
53	Alteration of mitochondrial protein PDHA1 in Lewy body disease and PARK14.Biochem Biophys Res Commun. 2017 Aug 5;489(4):439-444. doi: 10.1016/j.bbrc.2017.05.162. Epub 2017 May 28.
54	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease.Autophagy. 2018;14(8):1404-1418. doi: 10.1080/15548627.2018.1461294. Epub 2018 Jul 28.
55	PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease.Neurosci Lett. 2017 Apr 3;645:40-45. doi: 10.1016/j.neulet.2017.02.027. Epub 2017 Feb 14.
56	Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease.J Mol Neurosci. 2015 Sep;57(1):48-62. doi: 10.1007/s12031-015-0576-8. Epub 2015 May 17.
57	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies.Neurobiol Aging. 2016 Sep;45:107-108. doi: 10.1016/j.neurobiolaging.2016.03.021. Epub 2016 Mar 24.
58	REM sleep without atonia as prodromal marker of Lewy body disease: Fake news or the real deal?.Parkinsonism Relat Disord. 2019 Oct;67:34-35. doi: 10.1016/j.parkreldis.2019.09.017. Epub 2019 Sep 16.
59	Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain.Neurosci Lett. 2019 Jul 27;706:164-168. doi: 10.1016/j.neulet.2019.05.034. Epub 2019 May 19.
60	Differences in responses to the Rorschach test between patients with dementia with Lewy bodies and Alzheimer's disease -from the perspective of visuoperceptual impairment.Psychiatry Res. 2017 Nov;257:456-461. doi: 10.1016/j.psychres.2017.08.038. Epub 2017 Aug 18.
61	Autophagy mediators (FOXO1, SESN3 and TSC2) in Lewy body disease and aging.Neurosci Lett. 2018 Sep 25;684:35-41. doi: 10.1016/j.neulet.2018.06.052. Epub 2018 Jun 30.
62	SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.PLoS One. 2013 Oct 30;8(10):e77711. doi: 10.1371/journal.pone.0077711. eCollection 2013.
63	Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies.Parkinsonism Relat Disord. 2019 Jul;64:300-303. doi: 10.1016/j.parkreldis.2019.03.005. Epub 2019 Mar 15.
64	Effects of single and combined immunotherapy approach targeting amyloid protein and -synuclein in a dementia with Lewy bodies-like model.Alzheimers Dement. 2019 Sep;15(9):1133-1148. doi: 10.1016/j.jalz.2019.02.002. Epub 2019 Aug 1.
65	An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias.Mol Brain. 2017 Aug 11;10(1):36. doi: 10.1186/s13041-017-0316-9.
66	TIGAR inclusion pathology is specific for Lewy body diseases.Brain Res. 2019 Mar 1;1706:218-223. doi: 10.1016/j.brainres.2018.09.032. Epub 2018 Sep 26.
67	TMEM230 Accumulation in Granulovacuolar Degeneration Bodies and Dystrophic Neurites of Alzheimer's Disease.J Alzheimers Dis. 2017;58(4):1027-1033. doi: 10.3233/JAD-170190.
68	Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE-4/TOMM40 long poly-T repeat allele variants.Alzheimers Dement (N Y). 2019 Nov 20;5:814-824. doi: 10.1016/j.trci.2019.08.005. eCollection 2019.
69	Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein.J Biol Chem. 2011 Sep 30;286(39):34088-100. doi: 10.1074/jbc.M111.243907. Epub 2011 Aug 8.
70	A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer's Disease.Front Neurol. 2018 Mar 6;9:124. doi: 10.3389/fneur.2018.00124. eCollection 2018.
71	TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies.Neurobiol Dis. 2010 May;38(2):210-8. doi: 10.1016/j.nbd.2010.01.007. Epub 2010 Jan 18.
72	Cerebral amyloid angiopathy-related cognitive impairment: The search for a specific neuropsychological pattern.Rev Neurol (Paris). 2017 Nov;173(9):562-565. doi: 10.1016/j.neurol.2017.09.006. Epub 2017 Oct 6.
73	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study.Lancet Neurol. 2018 Jan;17(1):64-74. doi: 10.1016/S1474-4422(17)30400-3. Epub 2017 Dec 16.
74	GBA and APOE 4 associate with sporadic dementia with Lewy bodies in European genome wide association study.Sci Rep. 2019 May 7;9(1):7013. doi: 10.1038/s41598-019-43458-2.
75	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders.Neurology. 2015 Dec 8;85(23):2016-25. doi: 10.1212/WNL.0000000000002170. Epub 2015 Nov 11.
76	DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients.Eur J Neurol. 2015 Sep;22(9):1323-5. doi: 10.1111/ene.12770.
77	Cerebrospinal fluid levels of alpha-synuclein, amyloid , tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.Neurosci Lett. 2020 Jan 10;715:134564. doi: 10.1016/j.neulet.2019.134564. Epub 2019 Nov 13.
78	Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.Sci Rep. 2019 Nov 20;9(1):17222. doi: 10.1038/s41598-019-53638-9.
79	The PPARGC1A locus and CNS-specific PGC-1 isoforms are associated with Parkinson's Disease.Neurobiol Dis. 2019 Jan;121:34-46. doi: 10.1016/j.nbd.2018.09.016. Epub 2018 Sep 17.
80	The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.J Neuroimaging. 2019 Nov;29(6):712-720. doi: 10.1111/jon.12643. Epub 2019 Jun 14.
81	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.Sci Rep. 2019 May 24;9(1):7803. doi: 10.1038/s41598-019-44173-8.
82	LRP10 in autosomal-dominant Parkinson's disease.Mov Disord. 2019 Jun;34(6):912-916. doi: 10.1002/mds.27693. Epub 2019 Apr 9.
83	Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant -synuclein in presynapses in Lewy body disease.J Neuropathol Exp Neurol. 2011 Oct;70(10):879-89. doi: 10.1097/NEN.0b013e3182303745.